Skip to content

Biobank: Analysis of the immune system against viral infections

Biobank: Analysis of the immune system against viral infections

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00039532
Enrollment
10000
Registered
2026-03-26
Start date
2021-02-10
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

viral infection

Interventions

Group 1: A biobank is to be established containing samples from patients with acute and chronic viral infections. The samples will be used for research into viral infections, viral evolution, and immu

Sponsors

Institut für Virologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Participants are capable of giving consent • Past or acute viral infection, latent, chronic persistent, or expired viral infection

Exclusion criteria

Exclusion criteria: • Potential participant incapable of giving consent • Blood sampling poses a health risk

Design outcomes

Primary

MeasureTime frame
The goal is to establish a prospective biobank for research into viral infections. This includes basic research as well as applied research aimed at detecting diseases (diagnostics), predicting their course (prognosis), and developing treatments (therapy) and preventive measures (prevention). The purpose of the biobank is thus limited to a group of diagnoses and risk cohorts, but not to a single research question or disease.

Secondary

MeasureTime frame
- Investigation of the immune response to viral infections - Analysis of host-specific genetic determinants - Investigation of viral evolution - Comparison of acute, persistent, and chronic infection courses

Countries

Germany

Contacts

Public ContactJörg Timm

Institut für Virologie

joerg.timm@med.uni-duesseldorf.de+49211811

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026